Page 13 - Robert Berman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

REKR earnings call for the period ending June 30, 2021.

Published: May 13, 2021   -- Bob Linke appointed Chief Executive Officer   NEW HAVEN, Conn.--(BUSINESS WIRE)-- Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022. There are currently no Food and Drug Administration (FDA) approved therapies for the prevention or treatment of CIPN, a debilitating condition resulting from the off-target toxicity of many chemotherapy treatments. Osmol was founded by Dr...

Rekor Systems, Inc. (REKR) Q1 2021 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. Rekor Systems, Inc. (NASDAQ: REKR) Q1 2021 Earnings Call Good afternoon ladies and gentlemen, and welcome to today's Rekor Systems, Inc. conference call. My name is Darryl and I'll be your coordinator for today. [Operator Instructions] Before we get started, I'd like to read you the company's abbreviated safe harbor statement. I'd like to remind you that statements made in this conference call concerning future revenues, results of...

Photo: marcoventuriniautieri/Getty Images In March, the president of Rekor Systems Inc., Robert Berman, told investors that 2020 was a “transformative year.” The surveillance tech company’s platform, Rekor One, which converts regular cameras into automated license plate readers (ALPR), had proven alluring to cash-strapped state governments during the Covid-19 pandemic. Oklahoma, which has seen its tax revenue plummet alongside falling oil prices, announced a statewide rollout of Rekor One in November to track uninsured motorists. “The platform allows for real-time detection of non-com...

Hancock Jaffe Laboratories, Inc.: First U.S. Patent Issues on Hancock Jaffe VenoValve / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve. The patent is entitled Implantable Vein Frame and is U.S. patent number 10,959,841. The company recently announced that only twenty-eight (28) days after filing, the U.S. Food and Drug Administration (FDA) approved the company's Investigational Devic...